- Home
- CRBP vs RBKB Comparison
CRBP vs RBKB Comparison
Compare CRBP & RBKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- RBKB
- Stock Information
- Founded
- CRBP 2009
- RBKB 1860
- Country
- CRBP United States
- RBKB United States
- Employees
- CRBP N/A
- RBKB N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- RBKB Banks
- Sector
- CRBP Health Care
- RBKB Finance
- Exchange
- CRBP Nasdaq
- RBKB Nasdaq
- Market Cap
- CRBP 96.5M
- RBKB 111.3M
- IPO Year
- CRBP N/A
- RBKB 2019
- Fundamental
- Price
- CRBP $8.22
- RBKB $11.75
- Analyst Decision
- CRBP Strong Buy
- RBKB
- Analyst Count
- CRBP 10
- RBKB 0
- Target Price
- CRBP $53.56
- RBKB N/A
- AVG Volume (30 Days)
- CRBP 215.8K
- RBKB 46.8K
- Earning Date
- CRBP 08-05-2025
- RBKB 07-24-2025
- Dividend Yield
- CRBP N/A
- RBKB N/A
- EPS Growth
- CRBP N/A
- RBKB N/A
- EPS
- CRBP N/A
- RBKB N/A
- Revenue
- CRBP N/A
- RBKB $28,027,000.00
- Revenue This Year
- CRBP N/A
- RBKB N/A
- Revenue Next Year
- CRBP $270.04
- RBKB N/A
- P/E Ratio
- CRBP N/A
- RBKB N/A
- Revenue Growth
- CRBP N/A
- RBKB N/A
- 52 Week Low
- CRBP $4.64
- RBKB $7.30
- 52 Week High
- CRBP $61.90
- RBKB $12.73
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- RBKB 49.95
- Support Level
- CRBP $7.26
- RBKB $11.68
- Resistance Level
- CRBP $7.90
- RBKB $12.15
- Average True Range (ATR)
- CRBP 0.53
- RBKB 0.38
- MACD
- CRBP -0.01
- RBKB -0.05
- Stochastic Oscillator
- CRBP 78.59
- RBKB 44.44
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About RBKB Rhinebeck Bancorp Inc.
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one- to four-family residential real estate loans, and to purchase investment securities.